---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-029320"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2026-05-01T23:59:59+00:00"
generated_at: "2026-05-15T00:22:13.423549+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Senti Biosciences enters $40M convertible note agreement with Celadon; initial $10M tranche

## Summary
- Celadon Partners, largest stockholder, commits up to $40M via Senior Secured Convertible Notes; first tranche $10M.
- Notes convertible at $0.6261/share with full-ratchet anti-dilution; maturity 6 months from closing with 200% repayment.
- Upon conversion, Celadon would own 54.6% of Senti common stock, triggering a change in control.
- Proceeds to fund CMC and clinical trials for SENTI-202; potential CVR transaction tied to milestones up to $60M.
- Stockholder meeting required by Aug 31, 2026 to approve issuance beyond 19.99% exchange cap.

## SEC filing metadata
- accession: 0001628280-26-029320
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2026-05-01T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 5.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000162828026029320/0001628280-26-029320-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000162828026029320/snti-20260427.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-029320
- JSON: https://secwatch.observer/filing/0001628280-26-029320.json
- Plain text: https://secwatch.observer/filing/0001628280-26-029320.txt

## Source-grounded claims
- claim_id: 5ec9ae2e478a3435174ae26301f109270cdc90ac
  claim: Senti Biosciences, Inc. incurred convertible notes of $10.0 million with Celadon Partners SPV 24 affiliate at will not bear any interest unless an event of default has occurred maturing six months after the closing date of the Initial Notes.
  evidence_excerpt: the first tranche consists of $10.0 million in aggregate principal amount of Notes that are to be issued (the “Initial Notes”), subject to the satisfaction of certain specified closing conditions
  evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000162828026029320/0001628280-26-029320-index.htm
- claim_id: 47f6a8646143d7ffd325b6ddcfda7aae39ce944e
  claim: Senti Biosciences, Inc. entered into Securities Purchase Agreement with an entity affiliated with Celadon Partners SPV 24 valued at $40.0 million (effective 2026-04-27).
  evidence_excerpt: On April 27, 2026, Senti Biosciences Holdings, Inc. (the “Company”), Senti Holdings, Inc., a direct, wholly owned subsidiary of the Company (“Senti Holdings”), and Senti Biosciences, Inc., a direct wholly owned subsidiary of Senti Biosciences Holdings (“Senti Biosciences”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with one accredited investor (the “Investor”), pursuant to which Senti Holdings agreed to issue and sell in a private placement up to $40.0 million in aggregate principal amount of its Senior Secured Convertible Notes (the “Notes”) in up to two tranches, subject to the satisfaction of certain specified closing conditions.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000162828026029320/0001628280-26-029320-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.